Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 09:30PM GMT
Release Date Price: €17.7 (-5.35%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with Mirum.

Format is a little different this year. We don't have to all shuffle over to another room for Q&A. The Q&A is going to happen right here after the presentation concludes. (Operator Instructions)

So with that out of the way, let me turn it over to Mirum's CEO, Chris Peetz.

Christopher Peetz
Mirum Pharmaceuticals, Inc. - President, CEO & Director

Thanks, Jess, and thanks, everyone, for the interest in Mirum. Excited to walk through the story here today.

I'm going to just make some kind of overview comments, dive a little bit deeper into our commercial program in Alagille syndrome, talk about some of the pipeline across pediatric and adult cholestasis and then kind of wrap up the story and why we're so excited about 2023.

I'd be making forward-looking statements. So I'll refer you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot